Prevalence and predictors of hypertension in cardiac recipients

Aim. The study was aimed to assess the prevalence and risk factors of hypertension in cardiac recipients.

Materials and methods. End-stage heart failure patients who received cardiac transplant between 01.01.2013 and 31.12.2016 in V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs (Moscow) and survived 3 months after surgery were included and followed up for 999.4 ± 774.3 (108–1587) days. Young patients (<18 y/o) and patients after repeated (n = 18) or multi-organ transplantation (n = 3) were excluded.

Results. 353 cardiac recipients aged 45.6 ± 1.6 years (18.1% females and 81.9% males) were enrolled into the study. Hypertension was prevalent in 17.6, 42.8, 62.3 and 71.4%, respectively, before, in 3 months, in 1 year, and 3+ years after the transplantation. The study revealed significant relationship between post-transplant hypertension incidence and pre-op body mass index (р = 0.026), serum creatinine (р < 0.001), preexisting hypertension (RR = 1.36, р = 0.022) and renal failure, as well as donor heart posterior wall thickness (р = 0.034), post-transplant dialysis (RR = 1.85, р < 0.001), and antibody mediated rejection episodes (RR = 1.7, р = 0.001). Uncontrolled hypertension in cardiac recipients was related to poor compliance and new-onset post-transplant renal failure.

Conclusion. Hypertension is highly prevalent among our population of cardiac recipients. The combination of various etiologic mechanisms, multiplex therapy and subjective factors calls for the careful individual patient management.

1. Готье СВ, Шевченко АО, Попцов ВН. Пациент с трансплантированным сердцем (ISBN 978-5-94789- 648-0). М.: Триада, 2014. 144 c. Gautier SV, Shevchenko AO, Poptsov VN. Patsient s transplantirovannym serdtsem (ISBN 978-5-94789-648-0). M.: Triada, 2014. 144.

2. Lund LH, Edwards LB, Dipchand AI et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Heart Transplantation Report- 2016. The Journal of Heart and Lung Transplantation. 2016; 35 (10): 1158–1169.

3. Patel P, LaPorte K, Carroll M et al. Understanding Hypertension in Pediatric Patients After Heart Transplantation. The Journal of Heart and Lung Transplantation. 2017; 36 (4): S266.

4. Piepoli MF, Hoes AW, Agewall S et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European Heart Journal. 2016; 37 (29): 2315–2381.

5. Levy WC, Mozaffarian D, Linker DT et al. The Seattle Heart Failure Model. Circulation. 2006; 113 (11): 1424– 1433.

6. Lázaro S. Hypertension After Heart Transplantation: Predictive Factors and Number and Classes of Drugs for Its Management. Transplantation Proceedings. 2008; 40 (9): 3051–3052.

7. Page RL, Miller GG, Lindenfeld J. Drug therapy in the heart transplant recipient: part IV, drug-drug interactions. Circulation. 2005; 111: 230–239.

8. Martínez-Dolz L, Sánchez-Lázaro IJ, Almenar-Bonet L et al. Metabolic syndrome in heart transplantation: impact on survival and renal function. Transplant. International. 2013; 26: 910–918.

9. Metra M, Nodari S, Parrinello G et al. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. European Journal of Heart Failure. 2008; 10: 188–195.

10. Мареев ВЮ, Арутюнов ГП, Асташкин ЕИ и др. Острая декомпенсированная сердечная недостаточность. Согласованная позиция российских экспертов – 2014. Сердечная недостаточность. 2014; 15 (5): 321–336. Mareev VYu, Arutyunov GP, Astashkin EI i dr. Ostraya dekompensirovannaya serdechnaya nedostatochnost’. Soglasovannaya pozitsiya rossiyskikh ekspertov – 2014. Serdechnaya nedostatochnost’. 2014; 15 (5): 321–336.

11. Чазова ИЕ, Фомин ВВ, Разуваева МА, Вигдорчик АВ. Резистентная и неконтролируемая артериальная гипертония в Российской Федерации: эпидемиологическая характеристика и подходы к лечению (Российский регистр неконтролируемой и резистентной артериальной гипертонии, исследование «регата » – «резистентная гипертония артериальная»). Кардиологический вестник. 2011; 6 (1 (XVIII): 40–48. Chazova IE, Fomin VV, Razuvaeva MA, Vigdorchik AV. Rezistentnaya i nekontroliruemaya arterial’naya gipertoniya v Rossiyskoy Federatsii: epidemiologicheskaya kharakteristika i podkhody k lecheniyu (Rossiyskiy registr nekontroliruemoy i rezistentnoy arterial’noy gipertonii, issledovanie «regata » – «rezistentnaya gipertoniya arterial’naya»). Kardiologicheskiy vestnik. 2011; 6 (1 (XVIII): 40–48.

12. Шевченко ОП. Фиксированная низкодозовая комбинация лизиноприла и гидрохлортиазида в профилактике сердечно-сосудистых событий у больных артериальной гипертонией. Рациональная фармакотерапия в кардиологии. 2010; 6 (5): 697–702. Shevchenko OP. Fiksirovannaya nizkodozovaya kombinatsiya lizinoprila i gidrokhlortiazida v profilaktike serdechno-sosudistykh sobytiy u bol’nykh arterial’noy gipertoniey. Ratsional’naya farmakoterapiya v kardiologii. 2010; 6 (5): 697–702.

13. Canzanello VJ, Textar SC, Taler SJ et al. Late hypertension after liver transplantation: A comparison of cyclosporine and tacrolimus (FK 506). Liver transplantation and surgery. 1998; 4: 328–334.

14. Kahan BD. Cyclosporine nephrotoxicity: pathogenesis, prophylaxis, therapy, and prognosis. The American Journal of Kidney Diseases. 1986; 8: 323–331.

15. Porter GA, Bennett WM, Sheps SG. Cyclosporine-associated hypertension. National High Blood Pressure Education Program. Archives of Internal Medicine. 1990; 150: 280– 283.

16. Bennett AL, Ventura HO. Hypertension in Patients with Cardiac Transplantation. Med. Clin. 2017; 101: 53–64.

17. Shevchenko AO, Tunyaeva IU, Nasyrova AA. Common carotid artery wall rigidity index is a mаrker of cardiac allograft rejection. The Journal of Heart and Lung Transplantation. 2015; 4S; S298.

18. Глезер МГ, Деев АД. Как увеличить эффективность антигипертензивной терапии в реальной клинической практике: результаты российской наблюдательной программы «Форсаж». Кардиология. 2016; 56 (1): 18–24. Glezer MG, Deev AD. Kak uvelichit’ effektivnost’ antigipertenzivnoy terapii v real’noy klinicheskoy praktike: rezul’taty rossiyskoy nablyudatel’noy programmy «Forsazh». Kardiologiya. 2016; 56 (1): 18–24.